Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: Interim analysis of 3881 patients

Takao Koike, Masayoshi Harigai, Shigeko Inokuma, Naoki Ishiguro, Junnosuke Ryu, Tsutomu Takeuchi, Syuji Takei, Yoshiya Tanaka, Kyoko Ito, Hisashi Yamanaka

Research output: Contribution to journalArticle

107 Citations (Scopus)

Abstract

Objective: An interim analysis of an all-patient postmarketing surveillance programme in Japan to investigate the safety of tocilizumab for the treatment of rheumatoid arthritis (RA) in the real world. Methods: This analysis included 3881 patients. Patients received 8 mg/kg of tocilizumab every 4 weeks, and were observed for 28 weeks. Data on baseline characteristics and adverse events (AE) were collected. Results: Total and serious AE were reported as 167 and 27 events/100 patient-years, respectively. The most frequent AE and serious AE were infections. Logistic regression analysis identified the following risk factors for the development of serious infection: concurrent or medical history of respiratory disorders; prednisolone dose at baseline ≥5 mg/day; and age ≥65 years. Twenty-five patients died, and the standardised mortality ratio, with the Japanese general population in 2008 as reference, was 1.66, similar to the results from the Japanese cohort study for RA patients. Conclusions: Tocilizumab is acceptably safe in the real clinical setting. Tocilizumab needs to be used with consideration of the benefit-risk balance to avoid serious infections in elderly patients and those on high doses of corticosteroids or with a concurrent or medical history of respiratory disorders.

Original languageEnglish
Pages (from-to)2148-2151
Number of pages4
JournalAnnals of the Rheumatic Diseases
Volume70
Issue number12
DOIs
Publication statusPublished - 2011 Dec

Fingerprint

Rheumatoid Arthritis
Japan
Prednisolone
Regression analysis
Infection
Logistics
Adrenal Cortex Hormones
tocilizumab
Cohort Studies
Logistic Models
Regression Analysis
Safety
Mortality
Population

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Allergy

Cite this

Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan : Interim analysis of 3881 patients. / Koike, Takao; Harigai, Masayoshi; Inokuma, Shigeko; Ishiguro, Naoki; Ryu, Junnosuke; Takeuchi, Tsutomu; Takei, Syuji; Tanaka, Yoshiya; Ito, Kyoko; Yamanaka, Hisashi.

In: Annals of the Rheumatic Diseases, Vol. 70, No. 12, 12.2011, p. 2148-2151.

Research output: Contribution to journalArticle

Koike, T, Harigai, M, Inokuma, S, Ishiguro, N, Ryu, J, Takeuchi, T, Takei, S, Tanaka, Y, Ito, K & Yamanaka, H 2011, 'Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: Interim analysis of 3881 patients', Annals of the Rheumatic Diseases, vol. 70, no. 12, pp. 2148-2151. https://doi.org/10.1136/ard.2011.151092
Koike, Takao ; Harigai, Masayoshi ; Inokuma, Shigeko ; Ishiguro, Naoki ; Ryu, Junnosuke ; Takeuchi, Tsutomu ; Takei, Syuji ; Tanaka, Yoshiya ; Ito, Kyoko ; Yamanaka, Hisashi. / Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan : Interim analysis of 3881 patients. In: Annals of the Rheumatic Diseases. 2011 ; Vol. 70, No. 12. pp. 2148-2151.
@article{b1d86df9636045dda4ab34bc10353597,
title = "Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: Interim analysis of 3881 patients",
abstract = "Objective: An interim analysis of an all-patient postmarketing surveillance programme in Japan to investigate the safety of tocilizumab for the treatment of rheumatoid arthritis (RA) in the real world. Methods: This analysis included 3881 patients. Patients received 8 mg/kg of tocilizumab every 4 weeks, and were observed for 28 weeks. Data on baseline characteristics and adverse events (AE) were collected. Results: Total and serious AE were reported as 167 and 27 events/100 patient-years, respectively. The most frequent AE and serious AE were infections. Logistic regression analysis identified the following risk factors for the development of serious infection: concurrent or medical history of respiratory disorders; prednisolone dose at baseline ≥5 mg/day; and age ≥65 years. Twenty-five patients died, and the standardised mortality ratio, with the Japanese general population in 2008 as reference, was 1.66, similar to the results from the Japanese cohort study for RA patients. Conclusions: Tocilizumab is acceptably safe in the real clinical setting. Tocilizumab needs to be used with consideration of the benefit-risk balance to avoid serious infections in elderly patients and those on high doses of corticosteroids or with a concurrent or medical history of respiratory disorders.",
author = "Takao Koike and Masayoshi Harigai and Shigeko Inokuma and Naoki Ishiguro and Junnosuke Ryu and Tsutomu Takeuchi and Syuji Takei and Yoshiya Tanaka and Kyoko Ito and Hisashi Yamanaka",
year = "2011",
month = "12",
doi = "10.1136/ard.2011.151092",
language = "English",
volume = "70",
pages = "2148--2151",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",
number = "12",

}

TY - JOUR

T1 - Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan

T2 - Interim analysis of 3881 patients

AU - Koike, Takao

AU - Harigai, Masayoshi

AU - Inokuma, Shigeko

AU - Ishiguro, Naoki

AU - Ryu, Junnosuke

AU - Takeuchi, Tsutomu

AU - Takei, Syuji

AU - Tanaka, Yoshiya

AU - Ito, Kyoko

AU - Yamanaka, Hisashi

PY - 2011/12

Y1 - 2011/12

N2 - Objective: An interim analysis of an all-patient postmarketing surveillance programme in Japan to investigate the safety of tocilizumab for the treatment of rheumatoid arthritis (RA) in the real world. Methods: This analysis included 3881 patients. Patients received 8 mg/kg of tocilizumab every 4 weeks, and were observed for 28 weeks. Data on baseline characteristics and adverse events (AE) were collected. Results: Total and serious AE were reported as 167 and 27 events/100 patient-years, respectively. The most frequent AE and serious AE were infections. Logistic regression analysis identified the following risk factors for the development of serious infection: concurrent or medical history of respiratory disorders; prednisolone dose at baseline ≥5 mg/day; and age ≥65 years. Twenty-five patients died, and the standardised mortality ratio, with the Japanese general population in 2008 as reference, was 1.66, similar to the results from the Japanese cohort study for RA patients. Conclusions: Tocilizumab is acceptably safe in the real clinical setting. Tocilizumab needs to be used with consideration of the benefit-risk balance to avoid serious infections in elderly patients and those on high doses of corticosteroids or with a concurrent or medical history of respiratory disorders.

AB - Objective: An interim analysis of an all-patient postmarketing surveillance programme in Japan to investigate the safety of tocilizumab for the treatment of rheumatoid arthritis (RA) in the real world. Methods: This analysis included 3881 patients. Patients received 8 mg/kg of tocilizumab every 4 weeks, and were observed for 28 weeks. Data on baseline characteristics and adverse events (AE) were collected. Results: Total and serious AE were reported as 167 and 27 events/100 patient-years, respectively. The most frequent AE and serious AE were infections. Logistic regression analysis identified the following risk factors for the development of serious infection: concurrent or medical history of respiratory disorders; prednisolone dose at baseline ≥5 mg/day; and age ≥65 years. Twenty-five patients died, and the standardised mortality ratio, with the Japanese general population in 2008 as reference, was 1.66, similar to the results from the Japanese cohort study for RA patients. Conclusions: Tocilizumab is acceptably safe in the real clinical setting. Tocilizumab needs to be used with consideration of the benefit-risk balance to avoid serious infections in elderly patients and those on high doses of corticosteroids or with a concurrent or medical history of respiratory disorders.

UR - http://www.scopus.com/inward/record.url?scp=82755160877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82755160877&partnerID=8YFLogxK

U2 - 10.1136/ard.2011.151092

DO - 10.1136/ard.2011.151092

M3 - Article

C2 - 21852254

AN - SCOPUS:82755160877

VL - 70

SP - 2148

EP - 2151

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

IS - 12

ER -